Ajanta Pharma vs Eris Lifesciences: Share Price, Comparison and Key Differences

Ajanta Pharma vs Eris Lifesciences is a comparison specialty branded pharma investors look up when evaluating two profitable listed Indian pharmaceutical companies. Ajanta Pharma is a Mumbai-based company with a specialty branded generic model in India (ophthalmology, cardiology, dermatology) and a growing Africa and US institutional business. Eris Lifesciences is an Ahmedabad-based branded generics company focused on chronic disease therapy – diabetes, cardiovascular, thyroid and CNS – with a large, well-trained field force.

This Ajanta Pharma vs Eris Lifesciences article covers reach and market position, key products, latest declared results and stock valuation. The Ajanta Pharma vs Eris Lifesciences data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Ajanta Pharma vs Eris Lifesciences: Reach and Market Position

On the Ajanta Pharma side of the Ajanta Pharma vs Eris Lifesciences comparison, Ajanta Pharma has a focused branded sales team in India across ophthalmology, dermatology and cardiology, and exports branded generics to Africa and institutional generics to the US. Market capitalisation is Rs 43,386 Cr.

Click Here – Get Free Investment Predictions

On the Eris Lifesciences side of the Ajanta Pharma vs Eris Lifesciences comparison, Eris Lifesciences focuses on India’s branded chronic disease prescriptions with a large, highly specialised field force of medical representatives and a growing nutraceutical and OTC segment. Market capitalisation is Rs 19,255 Cr.

Ajanta Pharma vs Eris Lifesciences: Key Products and Business Mix

In the Ajanta Pharma vs Eris Lifesciences product comparison, Ajanta Pharma offers: Ajanta Pharma earns from India branded generics, Africa branded generics and US institutional sales. EPS is Rs 90.82. PE is 38.23x, ROE 23.33 percent, D/E 0.06, Div 0.81 percent.

For Eris Lifesciences in this Ajanta Pharma vs Eris Lifesciences breakdown: Eris Lifesciences earns from chronic disease branded generics in diabetes (Kinedak, Glimisave, Tendia), cardiology, thyroid and CNS. EPS is Rs 48.04. PE is 28.92x, ROE 15.87 percent, D/E 0.60.

Ajanta Pharma vs Eris Lifesciences: Latest Results

The Ajanta Pharma vs Eris Lifesciences results for Ajanta Pharma: Ajanta Pharma has a market cap of Rs 43,386 Cr and PE of 38.23x. ROE is 23.33 percent – among the highest in mid-size Indian pharma. Near-zero debt and consistent dividends. Ajanta is 2.3 times larger than Eris.

The Ajanta Pharma vs Eris Lifesciences results for Eris Lifesciences: Eris Lifesciences has a market cap of Rs 19,255 Cr and PE of 28.92x. ROE is 15.87 percent. Eris is cheaper on PE than Ajanta. D/E of 0.60 reflects acquisitions in the chronic disease segment.

Compare Ajanta Pharma and Eris Lifesciences Fundamentals on the Univest Screener

Ajanta Pharma vs Eris Lifesciences: Stock and Valuation

The Ajanta Pharma vs Eris Lifesciences stock comparison uses the latest available market data from Groww. Investors tracking Ajanta Pharma vs Eris Lifesciences should verify current prices on NSE or BSE before trading.

Ajanta Pharma vs Eris Lifesciences at current valuations: Ajanta trades at Rs 43,386 Cr market cap, PE 38.23x, ROE 23.33 percent. Eris trades at Rs 19,255 Cr market cap, PE 28.92x, ROE 15.87 percent. Ajanta has a higher ROE and a higher PE; Eris is cheaper with a meaningful chronic disease positioning.

Ajanta Pharma vs Eris Lifesciences: Quick Comparison Table

The Ajanta Pharma vs Eris Lifesciences comparison table below summarises the key metrics covered in this article side by side.

Parameter	Ajanta Pharma	Eris Lifesciences
Sector	Specialty pharma: ophthalmology, cardiology + Africa	Branded chronic: diabetes, cardiology, thyroid, CNS
Market Cap	Rs 43,386 Cr	Rs 19,255 Cr
P/E Ratio	38.23x	28.92x
ROE	23.33%	15.87%
Debt to Equity	0.06	0.60
Dividend Yield	0.81%	0.52%
Key Strength	High ROE, Africa branded generics, US institutional	Large chronic disease field force in India

Conclusion

The Ajanta Pharma vs Eris Lifesciences comparison above covers the key data points on reach, products, results and valuation. Ajanta Pharma vs Eris Lifesciences covers two profitable Indian specialty pharma companies with differentiated strategies. Ajanta has a high-ROE model with Africa exports and focused India specialty brands. Eris has a large chronic disease India franchise with a capital-efficient field force model. Ajanta Pharma vs Eris Lifesciences investors should review India prescription market share, Africa branded generic traction, Eris’s chronic portfolio additions, and field force productivity. Ajanta Pharma vs Eris Lifesciences both serve India’s growing chronic disease market – consult a SEBI-registered advisor.

Download the Univest iOS App or Univest Android App to track Ajanta Pharma and Eris Lifesciences live price and get daily stock recommendations.

Frequently Asked Questions

What specialties does Ajanta Pharma cover?

Ans. Ajanta Pharma focuses on ophthalmology (eye drops, surgical aids), dermatology (skin care branded generics) and cardiology in India, with branded generics across Africa (Nigeria, Kenya, Ghana, Ivory Coast).

What does Eris Lifesciences sell in India?

Ans. Eris sells branded chronic disease drugs – diabetes (Kinedak, Glimisave, Tendia), cardiovascular, thyroid (Eltroxin licence) and CNS – to specialists and physicians through its field force across India.

Which has a higher ROE, Ajanta or Eris?

Ans. Ajanta Pharma has a higher ROE of 23.33 percent versus Eris at 15.87 percent, reflecting its high-margin Africa business and efficient India branded model.

Does Ajanta Pharma pay dividends?

Ans. Yes. Ajanta pays a dividend yield of approximately 0.81 percent.

What is Africa branded generics?

Ans. Africa branded generics is a business model where Indian pharma companies sell branded version of generic drugs (like malaria treatment, antibiotics) to African markets where branded recognition commands premium pricing over unbranded generics.

Are Ajanta and Eris in Nifty 50?

Ans. Neither is in Nifty 50. Both are tracked in Nifty Pharma and Nifty 500 indices.

What chronic diseases does Eris specialise in?

Ans. Eris Lifesciences focuses on diabetes, cardiovascular (antihypertensives, lipid-lowering), thyroid disorders and CNS (antidepressants, antiepileptics) – all are growing therapy areas in India’s increasingly chronic-disease-burdened population.